Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1841 • ACR Convergence 2020
Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Salvador Zubirán National Institute of Health Sciences and Nutrition, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Bizkaia, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone treatment for several autoimmune diseases including Systemic Lupus Erythematosus (SLE). Recently, concerns arose regarding HCQ shortages for SLE patients,…
Abstract Number: 0245 • ACR Convergence 2020
Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record
April Barnado¹, Robert Carroll¹ and Lee Wheless¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with patients often presenting with non-specific symptoms that can cause delays in diagnosis. Phenotype risk scores…
Abstract Number: 0262 • ACR Convergence 2020
SLE Pregnancies: C4 as Predictor of Flares and Adverse Pregnancy Outcomes
Francesca Crisafulli¹, Laura Andreoli¹, Matteo Filippini¹, Micaela Fredi¹, Maria Chiara Gerardi¹, Roberto Gorla², Maria Grazia Lazzaroni¹, Daniele Lini¹, Cecilia Nalli², Marco Taglietti¹, Andrea Lojacono³, Sonia Zatti³, Cristina Zanardini³, Franco Franceschini¹ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ³Obstetrics and Gynecology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy
Background/Purpose: SLE pregnancies have an increased risk of Adverse Pregnancy Outcomes (APO). In clinical practice, low C3 and C4 levels are associated with active disease…
Abstract Number: 0278 • ACR Convergence 2020
Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study
Mehmet Hocaoglu¹, Mark Denis P. Davis², Shirley-Ann Osei-Onomah³, Jesse Dabit², Rachel Giblon², Thomas O'Byrne², Cynthia Crowson⁴ and Ali Duarte-Garcia², ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous chronic disease with potential for long lasting morbidity. Studies that provide incidence data on the entire spectrum…
Abstract Number: 0296 • ACR Convergence 2020
Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals
Carolina Munoz-grajales¹, Stephenie Prokopec², Dennisse Bonilla³, Earl D. Silverman⁴, Sindhu Johnson³, Arthur Bookman⁵, Zahi Touma⁶, Zareen Ahmad⁷, Linda Hiraki⁸, Paul Boutros⁹, Andrzej Chruscinski¹⁰ and Joan Wither³, ¹University of Toronto, Toronto, Canada, ²Ontario Institute for Cancer Research, Toronto, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁵Division of Rheumatology, University Health Network; 8Department of Medicine, University of Toronto; Division of Rheumatology, Toronto, Canada, ⁶University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada, ⁷Department of Medicine, University of Toronto; Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Department of Medicine, University of Toronto, Toronto, Canada, ⁹Department of Immunology, University of Toronto; Department of Medical Biophysics, University of Toronto; Department of Pharmacology and Toxicology, University of Toronto; Department of Human Genetics, University of California; Department of Urology, University of California; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California; Institute for Precision Health, University of California; Jonsson Comprehensive Cancer Centre, University of California, Toronto, Canada, ¹⁰Multi-Organ Transplant Program, University Health Network, Toronto, Canada
Background/Purpose: Within the Anti-Nuclear Antibody (ANA) associated Systemic Autoimmune Rheumatic Diseases (SARD), such as Systemic Lupus Erythematous (SLE), Sjögren’s Syndrome (SS), and Systemic Sclerosis (SSc),…
Abstract Number: 0442 • ACR Convergence 2020
Disparities in CoronaViridae Infection Are Readily Apparent in Rheumatology Patients Despite Use of Hydroxychloquine And/or Methotrexate
Maria Antonelli¹ and Nora Singer², ¹MHMC/CWRU, Cleveland, OH, ²The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: In the initial months of the SARS CoV2/COVID19 pandemic, broad use of off-label therapy with hydroxychloroquine (HCQ) was prescribed to reduce CoV2-related morbidity and…
Abstract Number: 0587 • ACR Convergence 2020
Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Alfredo Aguirre¹, Laura Trupin¹, Sarah Patterson², Kimberly DeQuattro², Patricia Katz³, Cristina Lanata², Stephanie Rush¹, Lindsey Criswell⁴, Maria Dall'Era⁵ and Jinoos Yazdany¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: The pandemic of coronavirus disease 19 (COVID-19) has led to widespread disruptions across the spectrum of healthcare. We sought to investigate barriers to medical…
Abstract Number: 0844 • ACR Convergence 2020
Rab4A Regulates Glomerulonephritis and Tryptophan Metabolism in Sle1.2.3. Lupus-prone Mice via Recycling of CD98
Brandon Wyman¹, Nick Huang¹, Zhiwei Lai¹, Mark Haas², Manuel Duarte¹, Joshua Lewis¹ and Andras Perl¹, ¹SUNY Upstate Medical University, Syracuse, NY, ²Cedars-Sinai, Los Angeles, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with an incompletely understood etiology. Previous work has identified Rab4A, a small GTPase responsible for endosomal…
Abstract Number: 0863 • ACR Convergence 2020
Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States
Diane Kamen¹, Julie Birt², Monica Hadi³, Nashmel Sargalo³, Ella Brookes³, Paul Swinburn³, Leslie Hanrahan⁴, Karin Tse⁵, Natalia Bello⁶, Kirstin Griffing², Maria Silk², Laure Delbecque⁷ and Anca Askanase⁸, ¹Medical University of South Carolina, Charleston, SC, ²Eli Lilly and Company, Indianapolis, IN, ³Evidera, London, United Kingdom, ⁴Carra Group, Milwaukee, WI, ⁵Lupus Foundation of America, DC, WA, ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Brussels, Belgium, ⁸Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Literature describes a fairly high degree of satisfaction with SLE therapies, despite patients reporting high rates of adverse event (1-2). The objectives of this…
Abstract Number: 0977 • ACR Convergence 2020
Expanded T Peripheral Helper Cells and Increased Pathologic B Cell Lung Infiltration in Pristane-induced Murine Lupus in the Absence of BCL6+ Tfh Cells
Runci Wang¹, Pui Lee², Peter Nigrovic³ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston
Background/Purpose: PD-1hi CXCR5- T peripheral helper (Tph) cells are highly expanded in RA and SLE patients. Like T follicular helper (Tfh) cells, human Tph cells…
Abstract Number: 1023 • ACR Convergence 2020
Epidemiology and Sociodemographic Distribution of Upper Gastrointestinal Bleeding Among Medicaid Beneficiaries with Systemic Lupus Erythematosus
Chang Xu¹, Molly Perencevich², Seoyoung Kim², Karen Costenbader³ and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have multiple risk factors for upper gastrointestinal bleeding (UGIB), including heightened susceptibility to infection and glucocorticoid, NSAID and…
Abstract Number: 1261 • ACR Convergence 2020
Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Antiphospholipid syndrome (APS) has been classified as the development of venous and/or arterial thromboses, and/or pregnancy morbidity, in the presence of persistently raised levels…
Abstract Number: 1277 • ACR Convergence 2020
Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus
Pankti Mehta¹, Komal Singh¹, Amita Aggarwal¹ and Seema Sharma¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at an increased risk of infection owing to immunosuppressive therapy along with coexistent immune dysregulation. It is…
Abstract Number: 1293 • ACR Convergence 2020
Factors Associated with Early Hospital Readmission in Systemic Lupus Erythematosus: Data from National Readmission Database
Rashmi Dhital¹, Joshua Baker², Paras Karmacharya³, Anthony Donato⁴ and Dilli Poudel², ¹Reading Hospital and Medical Center, West Reading, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester MN, ROCHESTER, MN, ⁴Reading Hospital and Medical Center, West Reading, PA
Background/Purpose: Early hospital readmission is a major healthcare burden. Studies evaluating factors associated with readmissions in rheumatic diseases are sparse. Our aim was to use…
Abstract Number: 1474 • ACR Convergence 2020
Early Peak of Cardiovascular Events Occurs Equally in Caucasians and African-American SLE but Is Attributed to Different Risk Factors
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: The classic bimodal pattern of morbidity/mortality in SLE highlighted that cardiovascular events occurred later in the natural history of SLE (Urowitz & Gladman. J…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].